A Mayo Clinic study has found that a shorter, lower-intensity course of radiation and chemotherapy after minimally invasive surgery for HPV-positive oropharyngeal squamous cell carcinoma significantly reduces treatment-related side effects while maintaining high cure rates. The findings were published in The Lancet Oncology.
This approach is a game-changer for patients, according to senior author Dr. Daniel Ma, a head and neck radiation oncologist at Mayo Clinic Comprehensive Cancer Center. The shorter and milder treatment regimen allows patients to recover faster and enjoy a better quality of life without compromising effectiveness.
Standard treatment for HPV-linked oropharyngeal cancer typically involves seven weeks of daily radiation with chemotherapy, or six weeks post-surgery. While effective, these often cause significant long-term side effects like jaw issues, dry mouth, taste changes, and swallowing difficulties due to high toxicity, greatly impacting quality of life for many patients in their 40s and 50s.
In the phase 3 trial, researchers compared standard treatment to a new method involving minimally invasive transoral surgery followed by a mild, two-week radiation course called de-escalated adjuvant radiation therapy (DART). DART uses about half the standard radiation dose and one-fifth the chemotherapy dose.
Results showed the less intensive treatment significantly reduced severe (grade 3 or higher) and moderate (grade 2) toxicity, meaning fewer adverse events and improved symptom burden for patients after treatment. Crucially, disease control rates were comparable to standard therapy for intermediate-risk patients.
For specific high-risk patients—those with five or more lymph nodes or disease extending beyond the nodes—standard treatment showed slightly better disease control, likely due to chemotherapy factors rather than radiation. These patients should still receive the standard six-week treatment.
The study involved 228 patients treated at Mayo Clinic in Minnesota and Arizona, representing the largest published cohort of patients receiving de-escalated treatment after surgery. Ongoing research continues to explore biomarkers to identify the best candidates for this treatment strategy.
Related Mayo Study Shows Shorter, Less Intensive Radiation Effective for HPV-Linked Throat Cancer
Related topics:
